Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E
Laboratory of Onco-Hematology and Pharmacology, Faculty of Medicine, Dijon, France.
Leukemia. 1995 Jun;9(6):1013-24.
Topoisomerase (topo) inhibitors induce enzyme-linked DNA breaks. Resulting DNA damage can lead to cell cycle arrest and/or cell death by apoptosis. The sensitivity of five human leukemic cell lines to topo I (camptothecin or CPT) and topo II (etoposide or VP-16) inhibitors varied widely (100-fold for CPT and 30-fold for VP-16). Three cell lines were more sensitive (BV173, HL60, U937) and two cell lines were resistant (K562, KCL22) to both drugs. None of these cell lines were selected for drug resistance and overexpressed mdr1 gene. Their sensitivity was not related to their doubling time nor to cell cycle repartition. The initial DNA damage (cleavable complexes) induced by topo I and II inhibitors was measured as DNA-protein crosslinks (DPC) using alkaline elution. Neither DPC level induced by 30-min treatment with CPT or VP-16 nor the levels of topo 1, topo II alpha and topo II beta mRNA were related to sensitivity. Electron microscopy and DNA fragmentation measured by filter elution and agarose gel electrophoresis demonstrated that apoptosis was induced by both drugs in the five cell lines. The kinetics of DNA fragmentation was related to cell sensitivity. At drug concentrations higher than IC50, DNA fragmentation increased very rapidly in the three sensitive, compared with the two resistant, cell lines. Continuous exposure to both drugs induced cell cycle arrest in either G2 or S phase that was related both to cell sensitivity and drug concentration. Comparison between cell lines indicated that the ability of cells to arrest cell cycle in G2 or S phase was related to their drug sensitivity and increased with cell resistance. In a given cell line, cell cycle progression was observed to be progressively inhibited by increasing drug concentrations. Treatment of synchronized cells demonstrated that highly cytotoxic drug concentration induced a complete inhibition of cell cycle progression. Altogether, these data suggest that the ability of leukemic cell lines to regulate cell cycle progression and to trigger apoptosis is more indicative of their sensitivity to topoisomerase poisons than cleavable complexes induced by these drugs.
拓扑异构酶(topo)抑制剂可诱导酶联DNA断裂。由此产生的DNA损伤可导致细胞周期停滞和/或通过凋亡导致细胞死亡。五种人白血病细胞系对拓扑异构酶I(喜树碱或CPT)和拓扑异构酶II(依托泊苷或VP-16)抑制剂的敏感性差异很大(CPT为100倍,VP-16为30倍)。三种细胞系(BV173、HL60、U937)对两种药物更敏感,两种细胞系(K562、KCL22)对两种药物均耐药。这些细胞系均未因耐药性而被选择,也未过度表达mdr1基因。它们的敏感性与其倍增时间或细胞周期分布无关。使用碱性洗脱法将拓扑异构酶I和II抑制剂诱导的初始DNA损伤(可裂解复合物)测定为DNA-蛋白质交联(DPC)。CPT或VP-16处理30分钟诱导的DPC水平以及拓扑异构酶1、拓扑异构酶IIα和拓扑异构酶IIβmRNA水平均与敏感性无关。电子显微镜以及通过滤膜洗脱和琼脂糖凝胶电泳测定的DNA片段化表明,两种药物均在这五种细胞系中诱导了凋亡。DNA片段化的动力学与细胞敏感性相关。在高于IC50的药物浓度下,与两种耐药细胞系相比,三种敏感细胞系中的DNA片段化增加非常迅速。持续暴露于两种药物会导致细胞周期停滞在G2期或S期,这与细胞敏感性和药物浓度均有关。细胞系之间的比较表明,细胞在G2期或S期停滞细胞周期的能力与其药物敏感性相关,并随细胞耐药性增加。在给定的细胞系中,观察到细胞周期进程随着药物浓度的增加而逐渐受到抑制。对同步化细胞的处理表明,高细胞毒性药物浓度会导致细胞周期进程完全抑制。总之,这些数据表明,白血病细胞系调节细胞周期进程和触发凋亡的能力比这些药物诱导的可裂解复合物更能表明它们对拓扑异构酶毒物的敏感性。